Literature DB >> 11384905

Plasma protein and lipoprotein distribution of clozapine.

R M Procyshyn1, N B Kennedy, S Marriage, K M Wasan.   

Abstract

OBJECTIVE: The authors' goal was to determine what effect dyslipidemia has on clozapine's plasma distribution.
METHOD: [(3)H]Clozapine plus cold clozapine (335 ng/ml) were incubated in plasma samples with varying total cholesterol, lipoprotein cholesterol, and triglyceride concentrations. Following incubation, the plasma was separated into its lipoprotein and lipoprotein-deficient fractions by density gradient ultracentrifugation and clozapine distribution was determined.
RESULTS: Compared with the plasma standard, significantly more clozapine was recovered in the very-low-density lipoprotein fraction, which contained elevated total cholesterol and triglycerides. Correlation analysis revealed a positive correlation between total plasma triglyceride concentration and clozapine recovery in this fraction.
CONCLUSIONS: In plasma samples with elevated triglycerides, clozapine shifts from the lipoprotein-deficient fraction to the very-low-density lipoprotein fraction. This redistribution of clozapine may affect the pharmacological activity of clozapine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384905     DOI: 10.1176/appi.ajp.158.6.949

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

1.  Do serum lipids predict response to clozapine treatment?

Authors:  Ric M Procyshyn; William G Honer; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

2.  The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influenced by differences in plasma lipid concentrations.

Authors:  S D Lee; K M Wasan; A Calcagni; M Avery; F McCush; C Chen
Journal:  Pharm Res       Date:  2006-05-04       Impact factor: 4.200

3.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

4.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

Review 5.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.